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ABSTRACT
Background: There is a growing literature on the association of SARS-CoV-2 and other chronic conditions, such as non-
communicable diseases. However, little is known about the impact of coinfection with tuberculosis. We aimed to compare
the risk of death and recovery, as well as time-to-death and time-to-recovery, in COVID-19 patients with and without
tuberculosis.
Methods: We created a 4:1 propensity score matched sample of COVID-19 patients without and with tuberculosis, using
COVID-19 surveillance data in the Philippines. We conducted a longitudinal cohort analysis of matched COVID-19 patients
as of May 17, 2020, following them until June 15, 2020. The primary analysis estimated the risk ratios of death and recov-
ery in patients with and without tuberculosis. Kaplan–Meier curves described time-to-death and time-to-recovery stratified
by tuberculosis status, and differences in survival were assessed using the Wilcoxon test.
Results: The risk of death in COVID-19 patients with tuberculosis was 2.17 times higher than in those without (95% CI:
1.40-3.37). The risk of recovery in COVID-19 patients with tuberculosis was 25% lower than in those without (RR ¼
0.75,05% CI 0.63-0.91). Similarly, time-to-death was significantly shorter (p¼ .0031) and time-to-recovery significantly longer
in patients with tuberculosis (p¼ .0046).
Conclusions: Our findings show that coinfection with tuberculosis increased morbidity and mortality in COVID-19 patients.
Our findings highlight the need to prioritize routine and testing services for tuberculosis, although health systems are dis-
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Introduction
As of July 2020, the global burden of the COVID-19 pan-
demic has reached 15 million cases, and has caused
large-scale outbreaks in many countries [1]. The COVID-
19 pandemic is a substantial strain to healthcare systems
worldwide, particularly in resource-limited settings with
high prevalence of comorbid conditions such as tuber-
culosis (TB). TB is a major cause of morbidity and mortal-
ity, and caused 1.4 million deaths in 2018, the main
global infectious cause of death [2]. TB disproportion-
ately affects low-and-middle income countries, where TB
epidemics are fuelled by coinfection with HIV/AIDS [3]
and multidrug resistance [4,5]. The pandemic has caused
disruptions of TB treatment and programmes [6,7],
which have disproportionately impacted socially disad-
vantaged communities with TB [8]. In particular, fewer
patients have sought medical treatment for TB, research
on TB has been reduced, availability of drugs against TB
has decreased, and food supply and nutritional support
have been limited during the pandemic [9].
The COVID-19 outbreak in the Philippines is a con-
tinuing public health crisis, with 12,513 reported cases
as of May 17, 2020 and over 130,000 cases as of July
2020. TB is also a major public health problem in the
Philippines with the third highest incidence of TB glo-
bally, and one million individuals have active TB [10].
Most of the research on SARS-CoV-2 has been con-
ducted in high-income countries, and studies suggest
worse outcomes in COVID-19 patients with other respira-
tory diseases, such as chronic obstructive pulmonary dis-
ease (COPD) [11,12] and asthma [13]. However, little is
known about the impact of coinfection with TB on
COVID-19 outcomes. Pulmonary TB causes destruction of
lung parenchyma [14], which may predispose COVID-19
patients with TB to aggressive disease and high mortal-
ity. We hypothesized that COVID-19 patients with previ-
ous or active TB may have worse clinical outcomes than
those without. This study compares the risk of and time-
to-death and recovery in COVID-19 patients with and
without TB coinfection in the Philippines.
Materials and methods
Data
Data was obtained from the Philippine national COVID-
19 surveillance implemented and managed by the
Philippine Department of Health Epidemiology Bureau
(DOH-EB). Data on COVID-19 cases were publicly avail-
able through the DOH DataDrop initiative [15], except
comorbidities data, which was provided by DOH-EB fully
de-identified from continuing surveillance efforts as part
of an ongoing outbreak investigation. Thus, institutional
review board approval was deemed unnecessary.
Study population
We included all reported COVID-19 cases in the
Philippines as of May 17, 2020, following them until
June 15, 2020. COVID-19 cases were confirmed with
positive real-time reverse transcription polymerase chain
reaction (RT-PCR) from laboratories accredited by the
DOH and the Research Institute for Tropical Medicine
(RITM) [16]. Information on confirmed cases were col-
lected using structured interviews by the physician or
nurse on duty at initial consultation as part of routine
surveillance using a case investigation form (CIF), filled
out manually or electronically. We used propensity score
matching to create similar populations of COVID-19
patients with and without previous and active TB. To
create the propensity scores, we predicted the risk of
having TB using logistic regression with the potential
confounders age, sex, and other comorbid conditions
(COPD, asthma, diabetes, hypertension, cancer, renal dis-
ease, cardiac disease, and autoimmune disorders). We
matched one COVID-19 patient with TB to four without,
using nearest neighbour matching of propensity scores,
a calliper of 0.05, and with no replacement. For a sec-
ondary analysis, we created a propensity score matched
subsample of COVID-19 patients admitted to hospital.
Exposure
Our main exposure of interest was confirmed TB, which
was defined as a history of or a current diagnosis of TB.
Comorbidity data and death certificate data encoded as
part of the CIF were used to determine the status of the
TB infection.
Outcomes
The two main outcomes of interest were (1) death and
(2) recovery. We modelled this as a dichotomous (yes/
no) variable, as well as a time-to-event variable. The
time-to-event variables for both primary outcomes were
the time from symptom onset to death or recovery.
Death was defined as deaths during active COVID-19,
and declared as a death by the DOH-EB. Recovery was
defined as cases declared recovered by the DOH-EB
based on criteria for testing (negative RT-PCR), clinical
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improvement, and additional days of quarantine.
Another secondary outcome was the relative risk of
admission and time-to-admission in the propensity score
matched sample.
Statistical analyses
Descriptive statistics were used to characterize the sam-
ple. Student’s t-test was used to assess differences in
age between patients with and without TB. Pearson chi-
square test was used to examine differences in gender,
comorbidities, health status and admission status. The
primary analysis estimated the relative risks (risk ratios)
of death and recovery with a modified Poisson regres-
sion with a robust variance estimator and a log link.
Kaplan–Meier curves stratified by TB status were used
to plot survival curves of the time-to-event variables.
Non-parametric analysis of differences in survival
between patients with and without TB was done using
the Wilcoxon test. Individuals were censored at their last
date of follow-up if they did not have the outcome of
interest. For the analysis of time-to-recovery, we cen-
sored subjects who were dead on the last day of admin-
istrative follow-up for the whole sample. This was done
to not raise the bias estimate of recovery by removing
patients who died as censored observations. All statis-
tical analyses were conducted in R 4.0.0 [17].
Results
Propensity score matching
The initial unmatched sample consisted of 12,513
COVID-19 patients, of which 113 (1.0%) had confirmed
TB. Sex differed significantly between patients with and
without TB (p< .001), as well as hypertension (p¼ .002)
and diabetes (p¼ .006) (Supplementary Table 1). We
removed all patients with missing covariates on varia-
bles from the propensity score matching, including
seven TB patients, and 4,510 COVID-19 patients were
included in the final propensity score-matched sample.
The final matched sample consisted of 530 patients,
with 106 cases with TB cases and 424 without. Matching
successfully created populations with similar baseline
characteristics (all p> .05; Table 1). The mean age of the
total sample was 48.9 years (SD ¼ 18.88; 95% CI: 47.2-
50.5), 70.4% were males, 13.4% (n¼ 71) died, and 67.7%
(n¼ 359) recovered. The unmatched sample of COVID-19
patients admitted to hospital consisted of 3,869 people,
of which 70 (1.8%) had confirmed TB. In the propensity
Table 1. Demographics and health status of the matched full sample and matched admitted subsample
by TB status.
Matched sample Overall (n¼ 530) No TB (n¼ 424) TB (n¼ 106) p Value
Age (mean (SD)) 48.86 (18.88) 48.84 (18.71) 48.92 (19.63) .968
Male (%) 373 (70.4) 300 (70.8) 73 (68.9) .794
Comorbidities (%)
Hypertension 109 (20.6) 87 (20.5) 22 (20.8) 1.000
Diabetes 67 (12.6) 53 (12.5) 14 (13.2) .974
Cancer 6 (1.1) 5 (1.2) 1 (0.9) 1.000
Renal cancer 16 (3.0) 12 (2.8) 4 (3.8) .849
Cardiac disease 41 (7.7) 33 (7.8) 8 (7.5) 1.000
Asthma 21 (4.0) 17 (4.0) 4 (3.8) 1.000
COPD 6 (1.1) 3 (0.7) 3 (2.8) .182
Autoimmune disease 0 (0) 0 (0) 0 (0) 1.000
Health status (%)
Died 71 (13.4) 46 (10.8) 25 (23.6) .001
Recovered 359 (67.7) 302 (71.2) 57 (53.8) .001
Admission status (%) .038
Admitted 303 (57.2) 236 (55.7) 67 (63.2)
Not admitted 162 (30.6) 140 (33.0) 22 (20.8)
Unknown 65 (12.3) 48 (11.3) 17 (16.0)
Admitted subsample Overall (n¼ 330) No TB (n¼ 264) TB (n¼ 66) p Value
Age, mean (SD) 49.50 (18.54) 49.29 (17.71) 50.33 (21.68) .683
Male (%) 235 (71.2) 187 (70.8) 48 (72.7) .879
Comorbidities (%)
Hypertension 80 (24.2) 64 (24.2) 16 (24.2) 1.000
Diabetes 51 (15.5) 41 (15.5) 10 (15.2) 1.000
Cancer 3 (0.9) 2 (0.8) 1 (1.5) 1.000
Renal cancer 13 (3.9) 9 (3.4) 4 (6.1) .524
Cardiac disease 27 (8.2) 20 (7.6) 7 (10.6) .581
Asthma 1 (0.3) 0 (0.0) 1 (1.5) .453
COPD 1 (0.3) 0 (0.0) 1 (1.5) .453
Autoimmune disease 0 (0) 0 (0) 0 (0) 1.000
Health status (%)
Died 50 (15.2) 32 (12.1) 18 (27.3) .004
Recovered 218 (66.1) 180 (68.2) 38 (57.6) .138
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score matched cohort of admitted patients, three TB
patients had missing covariates, and one TB patient had
no control match. The final subsample included 330
COVID-19 patients, of which 66 had TB (20.0%).
Matching of the admitted subsample also successfully
created populations with similar baseline characteristics
(all p> .05; Table 1).
Patients with TB had 2.17 times higher risk of death
than those without (95% CI: 1.40-3.37). When assessed
in patients admitted to hospital, those with TB had a
similar higher risk of death (RR ¼ 2.25, 95% CI: 1.35-
3.75). The risk of recovery in patients with TB was 25%
lower than in those without (RR ¼ 0.75, 0.63-0.91). The
risk of recovery was similar in admitted patients, but not
significant (RR ¼ 0.84, 95% CI: 0.68-1.06). There was a
20% higher risk of admission in patients with TB (RR ¼
1.20, 95% CI: 1.04-1.38) (Table 2).
Kaplan–Meier survival analysis (Figure 1) showed that
the time-to-death in patients with TB was significantly
shorter than in those without for both the propensity
score matched sample (p¼ .0031) and in the subsample
of admitted patients (p¼ .0052). The time-to-recovery in
patients with TB was significantly longer than in those
without for both the full sample (p¼ .0046) and admit-
ted only (p¼ .02) (Figure 1). The time-to-admission did
not differ significantly (p¼ .057) among those with and
without TB in the full matched sample.
Discussion
The ongoing SARS-CoV-2 pandemic poses a challenge
for TB prevention and treatment worldwide. Our find-
ings showed that COVID-19 patients with TB had a two-
fold increased risk of death, and were less likely to
recover. Moreover, time-to-death was shorter and time-
to-recovery longer than in patients without TB. Given
that SARS-CoV-2 has caused a substantial number of
deaths worldwide (greater than 700,000 deaths by July
2020) [1], some of the deaths can be attributable to the
increased risk of death and slower recovery in COVID-19
patients with TB. These deaths can be prevented by
continuing to provide essential TB services, particularly
in countries with high TB burden, where TB cases need
Table 2. Relative risks of death, recovery and admission in full
matched sample and matched admitted subsample.
RR (95% CI) p Value
Matched cohort (n¼ 530)
Death 2.17 (1.4-3.37) .001
Recovery 0.75 (0.63-0.91) .003
Admission 1.20 (1.04-1.38) .012
Admitted only (n¼ 330)
Death 2.25 (1.35-3.75) .002
Recovery 0.84 (0.68-1.06) .137
Figure 1. Survival analysis for (a) time-to-death in full matched sample (b) time-to-death in matched admitted subsample (c) time-to-recov-
ery in full matched sample (d) time-to-recovery in matched admitted subsample.
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to continue to be correctly diagnosed and promptly
treated. Moreover, our finding suggests that areas with
greater TB burden would have higher case fatality rates
of COVID-19, which is important for public health plan-
ning and resource allocation. As COVID-19 cases are con-
tinuing to increase in many low and middle income
countries with high TB incidence, such as countries in
Southern Africa, Latin America, and Asia [1], mitigation
strategies need to target individuals with TB in order to
reduce the global burden of COVID-19.
Our findings are consistent with preliminary findings
from the Western Cape province of South Africa, where
COVID-19 patients with a current TB diagnosis had a 2.5
times higher risk of death, and those with previous TB
had a 50% higher risk [18]. Other studies have examined
the association between TB and COVID-19; a case-con-
trol study in China demonstrated an increased suscepti-
bility of TB patients to SARS-CoV-2 infection, and
increased severity of symptom development [19].
Several studies have also described the interrelationship
of these two diseases, such as assessing deaths in
patients with TB and COVID-19 coinfection [20] and the
post-TB sequalae in a global cohort of TB patients with
COVID-19 [21], as well as case studies of more severe
outcomes in COVID-19 patients with TB [22,23].
However, studies with longer follow-ups and adequate
sample size needed to make inferential comparisons are
limited. To our knowledge, this is the first longitudinal
cohort study investigating the association between
COVID-19 and TB with sufficient sample size in a high-
burden TB setting.
There are a number of limitations of the study. We
used propensity score matching to adjust for confounding
factors. However, residual confounding could still be an
issue for variables we did not match. For example, we had
no data on HIV/AIDs in our cohort, and this might have
biased our estimates since patients with TB are more likely
to be infected with HIV. However, propensity score match-
ing on all specified comorbid conditions would reduce
confounding substantially, and any potential residual con-
founding would be limited. Moreover, as this data was
obtained from the Philippine national surveillance of
COVID-19, some dates for the time-to-event outcomes
were missing. In survival analyses, we excluded individuals
with missing dates, and conducted statistical tests to
ensure that the confounder distribution of the included
sample for each time-to-event analysis did not differ sig-
nificantly between patients with and without TB
(Supplementary Table 2). In addition, the main outcomes
death and recovery could potentially have some missing
data; the survival analysis accounted for missing data by
censoring on the last day of follow-up for patients without
the outcome. Furthermore, since the data were collected
as part of a larger surveillance effort, previous TB diagno-
sis and current TB disease were aggregated as confirmed
TB, and we were unable to distinguish between the inde-
pendent effects of these two groups separately; even so,
the consistently strong effect size demonstrates the con-
sequence of TB and COVID-19 co-infection, adding to the
body of evidence that TB worsens the prognosis of
COVID-19 patients. Additionally, in the interest of rapid
reporting of scientific findings during a pandemic, the
patients were only followed up for a short period of time,
and we were only able to determine the short-term out-
comes in TB cases with COVID-19. Future longitudinal
cohort studies need to establish the long-term outcomes
among those coinfected with TB and COVID-19.
Our results demonstrated a direct relationship
between COVID-19 and TB, but SARS-CoV-2 also indir-
ectly contributes to TB-related morbidity and mortality.
COVID-19 has and will continue to cause a substantial
strain to healthcare systems worldwide, and high mortal-
ity is predicted for TB patients due to TB programme
disruptions, diagnostic delays, treatment interruptions,
and lack of access to drugs [6,7,9]. Moreover, inaccess-
ibility of health facilities and reduced ability to pay for
medical costs disproportionately affect socially disadvan-
taged populations, compounding already existing health
inequalities, particularly in countries with already vulner-
able health and economic systems [24]. Our findings
highlight the need to continue prioritizing routine and
testing services for TB, despite disruptions in health and
social systems during the COVID-19 pandemic.
Moreover, since a large proportion of patients with TB
are coinfected with HIV, further research on the co-
occurrence of these three infections, as well as on other
endemic communicable and noncommunicable diseases
in high TB-burden countries, is important for accurate
assessment of the global burden of SARS-CoV-2. Future
studies investigating the relationship between TB and
COVID-19 are warranted to support appropriate plan-
ning and resource allocation, as SARS-CoV-2 continues
to spread around the world.
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